Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Lattice Biologics Ltd. (LBLTF)
Belgrade, MT, US
Lattice Biologics Ltd. is a biotechnology firm focused on developing, manufacturing, and commercializing biological products designed for bone regeneration. These solutions are utilized globally across dental, spinal, and general orthopedic indications. The company's innovative offerings include novel amniotic fluid-based therapies such as AmnioBoost and AmnioBlast. In addition, their product line features a broad range of allografts, encompassing traditional, spinal, particulate, soft tissue, dental, membrane and barrier, and demineralized bone matrix varieties. These versatile products serve numerous critical medical applications, from enhancing spinal fusion and aiding breast reconstruction post-mastectomy to promoting bone regeneration in foot and ankle surgeries and fostering skull healing after neurosurgery. They also play a role in improving wound repair for burn victims, facilitating hernia repair, addressing subchondral bone defects in knee and other joint surgeries, and supporting various sports medicine procedures, including anterior and posterior cruciate ligament repairs. The company's headquarters are located in Belgrade, Montana.
No mergers or acquisitions recorded for this company.
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% | -99.75% | -99.93% | -100.00% |
Revenue flow
Revenue by geography
Revenue by segment
Revenue composition
By product
By geography
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
-
Revenue growth Medical - Devices: +11.2%+12.6% ★ Q2'21: -100.0% (vs Q2'20)
-
EPS growth Medical - Devices: +28.5%-34.3% Q2'21: +93.8% (vs Q2'20)
-
FCF margin FCF growth · Medical - Devices: +30.9%+7.8%
-
EBIT margin Medical - Devices: +6.2%-17.9%
-
ROIC Medical - Devices: +3.3%— Q2'21: -102.6% (vs Q2'20)
-
Share dilution Medical - Devices: 0.0%+9.8% Q2'21: +28.8% (vs Q2'20)
-
Debt / EBITDA Net debt/EBITDA · Medical - Devices: -0.35×-53.77× Q2'21: 0.00× (vs Q2'20)
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
| Metric |
Sep 2024 actual |
Sep 2025 actual |
Sep 2026 1 Rev. Ana. 1 EPS Ana. |
Sep 2027 1 Rev. Ana. 1 EPS Ana. |
Sep 2028 1 Rev. Ana. 1 EPS Ana. |
Sep 2029 1 Rev. Ana. 1 EPS Ana. |
|---|---|---|---|---|---|---|
| Revenue |
5.16M
est.
|
5.16M
est.
|
9.55M
9.55M – 9.55M
+85.1% YoY
|
13.35M
13.35M – 13.35M
+39.9% YoY
|
18.02M
18.02M – 18.02M
+34.9% YoY
|
25.56M
25.56M – 25.56M
+41.8% YoY
|
| EBITDA |
-2.01M
est.
|
-2.01M
est.
|
-3.73M
-3.73M – -3.73M
-85.1% YoY
|
-5.21M
-5.21M – -5.21M
-39.9% YoY
|
-7.03M
-7.03M – -7.03M
-34.9% YoY
|
-9.97M
-9.97M – -9.97M
-41.8% YoY
|
| EBIT |
-2.54M
est.
|
-2.54M
est.
|
-4.70M
-4.70M – -4.70M
-85.1% YoY
|
-6.57M
-6.57M – -6.57M
-39.9% YoY
|
-8.86M
-8.86M – -8.86M
-34.9% YoY
|
-12.57M
-12.57M – -12.57M
-41.8% YoY
|
| Net Income |
-11.18M
est.
|
-11.18M
est.
|
-3.20M
-3.20M – -3.20M
+71.3% YoY
|
2.05M
2.05M – 2.05M
+164.0% YoY
|
4.01M
4.01M – 4.01M
+95.3% YoY
|
7.94M
7.94M – 7.94M
+98.2% YoY
|
| SGA |
4.95M
est.
|
4.95M
est.
|
9.17M
9.17M – 9.17M
+85.1% YoY
|
12.82M
12.82M – 12.82M
+39.9% YoY
|
17.30M
17.30M – 17.30M
+34.9% YoY
|
24.54M
24.54M – 24.54M
+41.8% YoY
|
| EPS |
-0.11
est.
|
-0.11
est.
|
-0.03
-0.03 – -0.03
+71.3% YoY
|
0.02
0.02 – 0.02
+164.0% YoY
|
0.04
0.04 – 0.04
+95.3% YoY
|
0.08
0.08 – 0.08
+98.2% YoY
|
Owner Earnings
Ownership Overview
Ownership breakdown not available.
No beneficial ownership filings recorded.
Institutional Activity (13F)
Institutional history not available.
Top holders not available.
ETF Ownership
This company is not held by any ETF in our universe.
Insider Activity
No insider activity available.
Insider history not available.
No recent insider transactions.
Executive team
Executive compensation
Executive compensation not available.
No CEO compensation history available.
Proxy statements
No proxy statements available for this company yet.
Recent SEC filings
No SEC filings available for this company yet.
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| Donna Medina | Interim Chief Financial Officer | 60.0K | female |
No data available for this company.
No Senate trading activity found for this company.
No House trading activity found for this company.
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for LBLTF
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
